Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 4;15(3):e35756.
doi: 10.7759/cureus.35756. eCollection 2023 Mar.

The Sigma Enigma: A Narrative Review of Sigma Receptors

Affiliations
Review

The Sigma Enigma: A Narrative Review of Sigma Receptors

Joseph Pergolizzi et al. Cureus. .

Abstract

The sigma-1 and sigma-2 receptors were first discovered in the 1960s and were thought to be a form of opioid receptors initially. Over time, more was gradually learned about these receptors, which are actually protein chaperones, and many of their unique or unusual properties can contribute to a range of important new therapeutic applications. These sigma receptors translocate in the body and regulate calcium homeostasis and mitochondrial bioenergetics and they also have neuroprotective effects. The ligands to which these sigma receptors respond are several and dissimilar, including neurosteroids, neuroleptics, and cocaine. There is controversy as to their endogenous ligands. Sigma receptors are also involved in the complex processes of cholesterol homeostasis and protein folding. While previous work on this topic has been limited, research has been conducted in multiple disease states, such as addiction, aging. Alzheimer's disease, cancer, psychiatric disorders, pain and neuropathic pain, Parkinson's disease, and others. There is currently increasing interest in sigma-1 and sigma-2 receptors as they provide potential therapeutic targets for many disease indications.

Keywords: alzheimers; calcium homeostasis; cancer; cholesterol homeostasis; mitochondrial bioenergetics; protein chaperones; protein folding; psychiatric disorders; receptors; sigma.

PubMed Disclaimer

Conflict of interest statement

Mark Coleman is on the Board of Directors of Axome Therapeutics. Joseph V. Perolizzi is the Executive Chairman and President of Advantx Pharmaceuticals, Inc.

Figures

Figure 1
Figure 1. The topology of a sigma-1 receptor
The N-terminus is green and blue, the transmembrane segment is shown in blue, and the C-terminus is red. The steroid binding domain-like (SBDL) regions are shown in aqua for 1 and yellow for 2, and both are located on the C-terminus The original art is licensed under Creative Commons and comes from [11]

References

    1. A brief history of opiates, opioid peptides, and opioid receptors. Brownstein MJ. Proc Natl Acad Sci U S A. 1993;90:5391–5393. - PMC - PubMed
    1. Crystal structure of the human σ1 receptor. Schmidt HR, Zheng S, Gurpinar E, Koehl A, Manglik A, Kruse AC. Nature. 2016;532:527–530. - PMC - PubMed
    1. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H. Proc Natl Acad Sci U S A. 1996;93:8072–8077. - PMC - PubMed
    1. Structural determinants of sigma receptor affinity. Largent BL, Wikström H, Gundlach AL, Snyder SH. https://pubmed.ncbi.nlm.nih.gov/2826991/ Mol Pharmacol. 1987;32:772–784. - PubMed
    1. Sigma receptors: biology and function. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. https://pubmed.ncbi.nlm.nih.gov/1964225/ Pharmacol Rev. 1990;42:355–402. - PubMed

LinkOut - more resources